Evogene Appoints Dr. Olga Nissan as VP of Business Development to Enhance Drug Discovery

Evogene Strengthens Leadership with Appointing Dr. Olga Nissan as VP of Business Development

Evogene Ltd., a prominent player in the realm of computational chemistry, announces the appointment of Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. This strategic move aligns with the company’s ambition to enhance its capabilities in the generative design of small molecules, particularly in the pharmaceutical and agricultural sectors. Dr. Nissan brings a wealth of experience from her previous roles in biotechnology and pharmaceuticals, where she has successfully combined scientific innovation with strategic business acumen. Her extensive background includes leadership positions such as CEO and Co-Founder of Protica Bio, Technology Manager at EcoPhage, and Senior Scientist at BiomX.

Dr. Nissan’s appointment comes at a pivotal time for Evogene, as the company seeks to leverage advancements in AI-driven science to create therapeutic solutions. Her academic credentials, including a PhD and postdoctoral research at the Weizmann Institute of Science, equip her with a strong foundation in biochemistry and proteomics, which are crucial for driving innovative research and development. Dr. Nissan expresses her excitement about joining Evogene, emphasizing the potential of AI technologies in transforming drug discovery and development into practical applications that can benefit patients and the healthcare sector.

Ofer Haviv, President and CEO of Evogene, underscores the significance of Dr. Nissan’s 15 years of experience in biotechnology, pharmaceuticals, and AI-enabled drug discovery. He notes that her expertise will be instrumental in expanding the company’s small-molecule discovery capabilities through their proprietary ChemPass AI technology. This appointment reflects Evogene’s commitment to fortifying its business development initiatives and pursuing impactful collaborations with industry leaders. By enhancing its strategic leadership, Evogene aims to translate scientific advancements into solutions that address pressing health challenges and contribute positively to global stakeholders.

In addition to Dr. Nissan's appointment, Evogene continues to focus on expanding its innovation portfolio in computational chemistry. The company is dedicated to fostering partnerships that can accelerate the development of novel therapeutic solutions. As the demand for AI-driven tools in drug discovery grows, Evogene is well-positioned to capitalize on its cutting-edge technologies and scientific expertise.

The strategic direction taken by Evogene, particularly with the onboarding of Dr. Nissan, signals a robust commitment to advancing its capabilities and enhancing its market presence. This development is anticipated to bolster Evogene’s role in the pharmaceutical landscape, paving the way for future breakthroughs in drug discovery and development.